Korea Adalimumab Biosimilar Market Size & Outlook, 2026-2034

Korea Adalimumab Biosimilar Market Insights

Deep Market Insights analysis indicates that the Korea Adalimumab Biosimilar Market size, valued at USD 28.7 Million in 2025, is expected to expand to USD 50.37 Million by 2034.
The Korea market is forecasted to expand at a CAGR of 6.42% spanning 2026–2034.
Adalimumab biosimilars held the leading position among By Type segments in 2025, based on market size.
Adalimumab biosimilars is projected to post the fastest growth rate, sustaining its position as the most attractive By Type segment during the forecast horizon.

In 2025, Korea accounted for 1.01% of the global Adalimumab Biosimilar Market size.
By 2034, United States is expected to lead the global Adalimumab Biosimilar Market in terms of market size.
Within Asia Pacific, China is projected to dominate the regional Adalimumab Biosimilar Market size by 2034.
Australia is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 63.1 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 28.7 Million
Market Size In 2034	USD 50.37 Million
Largest segment	Adalimumab biosimilars
Units	Revenue in USD Million
CAGR	6.42% (2026-2034)
Segmnetation Covered
By Type	Adalimumab biosimilars Interchangeable biosimilars High-concentration formulations Low-concentration formulations
By Indication	Rheumatoid arthritis Psoriasis Crohn’s disease Ulcerative colitis
By Route of Administration	Subcutaneous Prefilled syringes Auto-injectors Hospital administration
By End User	Hospitals Clinics Homecare Specialty pharmacies
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Adalimumab biosimilars	XX.x	XX.x	XX.x	12.05	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Interchangeable biosimilars	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
High-concentration formulations	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Low-concentration formulations	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Indication	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Rheumatoid arthritis	XX.x	XX.x	XX.x	12.74	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Psoriasis	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Crohn’s disease	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ulcerative colitis	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Subcutaneous	XX.x	XX.x	XX.x	12.74	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Prefilled syringes	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Auto-injectors	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Hospital administration	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	12.86	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Homecare	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x